Skip to NavigationSkip to content

cardiovascular disease

Eli Lilly's Trulicity approved in US to reduce cardiovascular events in type 2 diabetes patients

Eli Lilly’s Trulicity (duraglutide) has been awarded marketing authorisation from the FDA as a therapy to reduce major adverse cardiovascular events (MACE) in type 2 diabetes (T2D) patients with established cardiovascular (CV) disease or who exhibit multiple cardiovascular risk factors, it has been announced.

According to the manufacturer, this makes Trulicity the first and only type 2 diabetes therapy approved for this indication in primary and secondary prevention populations. It secured its first approval in the US back in 2014.

Novo's semaglutide injection and tablets get expanded FDA approval for type 2 diabetes with established CVD

Novo Nordisk has seen label expansions approved from the FDA for both its glucagon-like peptide-1 (GLP-1) analogue injection Ozempic (once-weekly semaglutide) and its GLP-1 oral tablet Rybelsus (oral semaglutide).

The expansions are indicated for the reduction of the risk of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack, or non-fatal stroke, in adult type 2 diabetes patients with established cardiovascular disease (CVD).

AstraZeneca's Farxiga meets Phase 3 primary endpoint in heart failure

New Phase 3 data has been unveiled for AstraZeneca’s Farxiga (dapagliflozin), confirming that the SGLT2 inhibitor met its primary composite endpoint when added to standard of care by achieving a “statistically-significant and clinically-meaningful reduction of cardiovascular death or the worsening of heart failure (defined as hospitalisation or an urgent heart failure visit)”, compared to placebo.

The data was derived from a study comprised of patients with reduced ejection fraction (HFrEF) when given standard of care treatment, including those with and without type-2 diabetes.

Bayer's Xarelto combo greenlighted by NICE for reducing CV events in artery disease

NICE has awarded final appraisal recommendation to Bayer’s Xarelto (rivaroxaban) at a dosage of 2.5mg twice daily in combination with aspirin 75-100mg once daily as an option for preventing atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) who are at high risk of ischaemic events.

Lilly and Boehringer's Trajenta matches glimepiride in delaying cardiovascular events in type 2 diabetes patients

Boehringer Ingelheim and Eli Lilly’s Trajenta (linagliptin) met its primary endpoint in a recent trial, it has emerged, proving itself non-inferior to glimepiride in its ability to prolong the amount of time before the first occurrence of cardiovascular (CV) death, non-fatal myocardial infarction or non-fatal stroke in type 2 diabetes patients.

The CAROLINA trial – the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor – examined the efficacy of Trajenta in 6,033 patients with type 2 diabetes in addition to established CV disease or i

China's NMPA approves Amgen's Repatha to reduce cardiovascular event risk

Amgen has announced that its proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor Repatha (evolocumab) has secured approval by China’s drug regulator, the National Medical Products Administration (NMPA), to reduce the risk of myocardial infarction, stroke and coronary revascularisation in adult patients with established atherosclerotic cardiovascular disease (ASCVD).

The decision makes the drug the first PCSK9 inhibitor available in the nation for this indication.

Europe expands approved indication of Amgen's Repatha in cardiovascular disease

Amgen has revealed that its PCSK9 inhibitor Repatha (evolocumab) has received approval from the European Commission in a new indication: to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels in adult patients with established atherosclerotic cardiovascular disease, such as myocardial infarction, stroke or peripheral arterial disease.

Pfizer taps real world evidence for CVD in new partnership

BC Platforms, a company that focuses on genomic data managements and analysis, has announced that it has partnered with Pfizer to generate real world evidence (RWE) in atrial fibrillation patients

The collaboration will see BC Platforms analyse anonymised data from Turku University Hospital, in Finland, alongside other health care providers to develop RWE for the use of treating cardiovascular diseases.

12% of the UK have hearts ten years older than they are, Public Health England finds

New findings from Public Health England (PHE)’s Heart Age Test indicate that around 10% of men in the UK are suffering from an ‘older’ heart. The study gathered the data of 1.2 million people via an online test which began earlier this year. It was found that 167,000 people, or 12%, had a ‘heart age’ of at least ten years older than true age; of this number, 64% were men.

Where will the next cardiovascular breakthrough come from?

Published on 17/08/17 at 11:03am

British Heart Foundation’s Jennifer Mitchell, Research Communications Officer, explains the work they are doing to find the next breakthrough treatment for cardiovascular disease.

Over the past 50 years the number of people in the UK dying of cardiovascular disease each year has halved. This reduction in deaths can largely be attributed to an increase in society’s understanding of heart disease and the improvements in lifestyle and treatments that this knowledge has led to.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches